Phathom Pharmaceuticals (PHAT) Retained Earnings (2018 - 2026)

Phathom Pharmaceuticals (PHAT) has 9 years of Retained Earnings data on file, last reported at -$1.5 billion in Q1 2026.

• On a quarterly basis, Retained Earnings fell 11.59% year-over-year to -$1.5 billion in Q1 2026; TTM through Mar 2026 was -$1.5 billion, a 11.59% decrease from a year earlier, with the FY2025 full-year figure at -$1.5 billion, down 17.52% from the prior year.
• Retained Earnings for Q1 2026 stood at -$1.5 billion, down from -$1.5 billion in the prior quarter.
• Over the last five years, Retained Earnings for PHAT reached as high as -$570.0 million in Q1 2022 and fell as low as -$1.5 billion in Q1 2026.
• Historically, Retained Earnings has averaged -$1.0 billion across 5 years, with a median of -$1.0 billion in 2024.
• Across the five-year window, Retained Earnings tumbled 39.98% in 2024 and retreated 11.59% in 2026, its largest moves.
• Year by year, Retained Earnings stood at -$727.1 million in 2022, then fell by 27.73% to -$928.7 million in 2023, then sank by 36.0% to -$1.3 billion in 2024, then slipped by 17.52% to -$1.5 billion in 2025, then dropped by 2.05% to -$1.5 billion in 2026.
• Per Business Quant data, the three most recent Retained Earnings figures were -$1.5 billion in Q1 2026, -$1.5 billion in Q4 2025, and -$1.5 billion in Q3 2025.